| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_241ab9b343eb0d6967c5e6adbfa32b01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_985ef30c0b9b02be2358e4b3d9a48889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7f598841affc03e1e4fe10c9378a413 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate |
2008-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42cdceb5b4cc1c313a550950772dfa00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c797d905a45cb442a342ee07055e52b |
| publicationDate |
2009-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009033095-A2 |
| titleOfInvention |
Humanized pai-1 antibodies |
| abstract |
The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-I to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-I by converting PAI-I to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-I for the detection, diagnosis or treatment of a disease or condition associated with PAI-I or a combination thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2010137160-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2436385-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021260139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021155440-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11143659-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2436385-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7223069-B2 |
| priorityDate |
2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |